<DOC>
	<DOCNO>NCT01926587</DOCNO>
	<brief_summary>This study , Phase I/II clinical trial three part : Phase I Dose Escalation , Phase II , Part 1 RPTD Cohort , Phase II , Part 2 Expansion . The first two part complete . The Phase II , Part 2 Expansion ass treatment rigosertib combination azacitidine , measurable effect patient myelodysplastic syndrome ( MDS ) . Safety patient objective throughout part study .</brief_summary>
	<brief_title>Phase II Part 2 Expansion Oral Rigosertib Combination With Azacitidine</brief_title>
	<detailed_description>This Phase I/II open-label , single-arm , dose-escalating , multicenter study , three part : Phase I Dose Escalation , Phase II , Part 1 RPTD Cohort , Phase II , Part 2 Expansion , patient myelodysplastic syndrome ( MDS ) , acute myeloid leukemia ( AML ) , chronic myelomonocytic leukemia ( CMML ) receive subcutaneous ( SC ) intravenous ( IV ) azacitidine per approve label combination oral rigosertib . The first two part study complete . The Phase II Part 2 Expansion enroll 40 patient , randomize 1:1 2 cohort 20 patient , receive 1120 mg rigosertib 24 hour : either 560 mg BID , 840 mg morning 280 mg afternoon . The afternoon dose cohort must administer 3 PM ( ±1 hr ) least 2 hr lunch . In Phase II , Part 2 Expansion patient RAEB t/non-proliferative AML eligible , however patient CMML .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis MDS , CMML , RAEBt/nonproliferative AML ( defined 2030 % BMBL , WBC ≤ 25,000 x 10^9/L stable least 4 week without intervention ) accord World Health Organization ( WHO ) criteria French American British ( FAB ) classification either previously treat previously untreated . The diagnosis must confirm via BM aspirate and/or biopsy within 6 week prior Screening . Note : patient RAEBt/nonproliferative AML ( defined 2030 % BMBL , WBC ≤ 25,000 x 10^9/L stable least 4 week without intervention ) eligible Phase II Part 1 RPTD component study patient CMML eligible Phase II Part 2 Expansion study . If patient diagnose MDS , disease patient must classify Int1 , Intermediate2 ( Int2 ) Highrisk , accord International Prognosis Scoring System ( IPSS ) classification . Note : Only Int2 Highrisk patient enrol French site . Off treatment MDS , CMML , AML include erythropoiesisstimulating agent ( ESA ) , least 4 week prior Screening . Filgrastim ( GCSF ) allow study , clinically indicate . For AML patient , 1 prior salvage therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Willing adhere prohibition restriction specify protocol . The patient must sign informed consent form indicate she/he understands purpose procedure require study willing participate study . Prior treatment rigosertib ; Anemia due factor MDS , CMML , AML ( include hemolysis gastrointestinal bleeding ) . Any active malignancy within past year , except basal cell squamous cell skin cancer carcinoma situ cervix breast . Uncontrolled intercurrent illness . Active infection adequately respond appropriate therapy . Total bilirubin ≥ 2.0 mg/dL relate Gilbert 's disease hemolysis . Alanine transaminase ( ALT ) /aspartate transaminase ( AST ) ≥ 2.5 x upper limit normal ( ULN ) . Serum creatinine ≥ 2.0 mg/dL . Ascites require active medical management include paracentesis . Hyponatremia ( define serum sodium value &lt; 130 mEq/L ) . Female patient pregnant lactate . Female patient childbearing potential male patient partner childbearing potential unwilling follow strict contraception requirement entry throughout study , include 30day nontreatment followup period . Female patient reproductive potential negative blood urine pregnancy test Screening . Major surgery without full recovery major surgery within 3 week Screening . Uncontrolled hypertension ( define systolic pressure ≥ 160 mmHg and/or diastolic pressure ≥ 110 mmHg ) . New onset seizure ( within 3 month prior Screening ) poorly control seizure . Any investigational agent chemotherapy , radiotherapy , immunotherapy administer within 4 week prior Screening . Chronic use ( ˃ 2 week ) corticosteroid ( ˃ 10 mg/24 hr equivalent prednisone ) within 4 week Baseline/First Dose . Investigational therapy within 4 week Screening . Psychiatric illness social situation would limit patient 's ability tolerate and/or comply study requirement . Patients RAEBt/nonproliferative AML ( defined 2030 % BMBL , WBC ≤ 25,000 x 10^9/L stable least 4 week without intervention ) eligible participate Phase II Part 1 RPTD component study patient CMML eligible Phase II Part 2 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rigosertib</keyword>
	<keyword>ON 01910.Na</keyword>
	<keyword>azacitidine</keyword>
	<keyword>Vidaza</keyword>
</DOC>